Thyroid Eye Disease
RHHBYRoche HoldingCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Enspryng/Satralizumab (IL-6 Receptor Inhibitor) in Thyroid Eye Disease. The expected timing is based on the latest available company guidance and may change.
06/14/26:- FDA accepted priority sBLA for TED; decision expected October 15, 2026. 07/23/26:- Priority review for thyroid eye disease was reiterated; FDA decision will occur October 15, 2026.
Verification
Confirm timing and program details against the company announcement or filing.